Amye J. Tevaarwerk, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Amye Tevaarwerk, MD, obtained her medical degree from Washington University School of Medicine and completed an internship and residency in internal medicine at Barnes Jewish Hospital. Prior to entering clinical fellowship, she worked as a hospitalist for a year at Barnes Jewish Hospital in St. Louis. She completed a medical oncology fellowship at the University of Wisconsin. Her academic area of interest is breast oncology, with a focus on new drug development and women’s health issues as they relate to cancer survivorship. Dr. Tevaarwerk is a member of the UW Health Breast Center and part of Breast Disease-Oriented Working Group, through which multiple clinical trials in breast cancer are helping to find better treatments for those with cancer.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
University of Wisconsin Hospital and Clinics, Madison, WI
Barnes-Jewish Hospital, St. Louis, MO
Barnes-Jewish Hospital, St. Louis, MO
Washington University, St. Louis, MO, 2002
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Dr. Tevaarwerk’s research interests include breast oncology and Phase I clinical trials.
LoConte NK Razak AR Ivy P Tevaarwerk A Leverence R Kolesar J Siu L Lubner SJ Mulkerin DL Schelman WR Deming DA Holen KD Carmichael L Eickhoff J Liu G .
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs. 2015 Feb;33(1):169-76
[PubMed ID: 25318436]
Tevaarwerk AJ Wang M Zhao F Fetting JH Cella D Wagner LI Martino S Ingle JN Sparano JA Solin LJ Wood WC Robert NJ .
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014 Dec 10;32(35):3948-58
[PubMed ID: 25349302]
Burkard ME Wisinski KB Njiaju UO Donohue S Hegeman R Stella A Mansky P Shah V Goggins T Qamar R Dietrich L Kim K Traynor AM Tevaarwerk AJ .
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer. 2014 Jun;14(3):205-11
[PubMed ID: 24342730]
Rocque GB Wisinski KB Buhr KA Froeschner JL Jones N Donohue S Wiegmann D Sesto ME Tevaarwerk AJ .
Development and evaluation of a survey to assess survivor knowledge change after survivorship care plans: WiSDOM-B (Wisconsin Survey of cancer DiagnOsis and Management in Breast cancer). J Cancer Educ. 2014 Jun;29(2):270-7
[PubMed ID: 24343267]
Tevaarwerk AJ Wisinski KB Buhr KA Njiaju UO Tun M Donohue S Sekhon N Yen T Wiegmann DA Sesto ME .
Leveraging electronic health record systems to create and provide electronic cancer survivorship care plans: a pilot study. J Oncol Pract. 2014 May;10(3):e150-9
[PubMed ID: 24520142]
Zasadil LM Andersen KA Yeum D Rocque GB Wilke LG Tevaarwerk AJ Raines RT Burkard ME Weaver BA .
Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014 Mar 26;6(229):229ra43
[PubMed ID: 24670687]
Tevaarwerk AJ Gray RJ Schneider BP Smith ML Wagner LI Fetting JH Davidson N Goldstein LJ Miller KD Sparano JA .
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013 Mar 15;119(6):1140-8
[PubMed ID: 23065954]
Sesto ME Faatin M Wang S Tevaarwerk AJ Wiegmann DA .
Employment and retirement status of older cancer survivors compared to non-cancer siblings. Work. 2013;46(4):445-53
[PubMed ID: 24004736]
Tevaarwerk A Burkard ME Wisinski KB Shafer MM Davis LA Gogineni J Crone E Hansen KE .
Aromatase inhibitors and calcium absorption in early stage breast cancer. Breast Cancer Res Treat. 2012 Jul;134(1):245-51
[PubMed ID: 22350731]
Tevaarwerk A Wilding G Eickhoff J Chappell R Sidor C Arnott J Bailey H Schelman W Liu G .
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun;30(3):1039-45
[PubMed ID: 21225315]
Rocque G Onitilo A Engel J Pettke E Boshoven A Kim K Rishi S Waack B Wisinski KB Tevaarwerk A Burkard ME .
Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Res Treat. 2012 Jan;131(2):713-21
[PubMed ID: 22065290]
Lepeak L Tevaarwerk A Jones N Williamson A Cetnar J LoConte N .
Persistence in breast cancer disparities between African Americans and whites in Wisconsin. WMJ. 2011 Feb;110(1):21-5
[PubMed ID: 21473509]
Loconte NK Williamson A Gayle A Weiss J Leal T Cetnar J Mohammed T Tevaarwerk A Jones N .
Increasing Disparity in Colorectal Cancer Incidence and Mortality Among African Americans and Whites: A State's Experience. J Gastrointest Oncol. 2011;2(2):85-92
[PubMed ID: 21712962]
Leal T Tevaarwerk A Love R Stewart J Binkley N Eickhoff J Parrot B Mulkerin D .
Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. Clin Breast Cancer. 2010 Dec 1;10(6):471-6
[PubMed ID: 21147691]
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G .
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
Tevaarwerk AJ Holen KD Alberti DB Sidor C Arnott J Quon C Wilding G Liu G .
Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res. 2009 Feb 15;15(4):1460-5
[PubMed ID: 19228747]
Tevaarwerk AJ Kolesar JM .
Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31 Pt 2:2332-48
[PubMed ID: 20110044]